From Bench to Bedside and Back Again

From bedside to bench and back again.

GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.

From the discovery of the platelet glycoprotein (GP) IIb/IIIa and identification of its central role in haemostasis, the integrin GPIIb/IIIa (αIIbβ3, CD41/CD61) was destined to be an anti-thrombotic target. The subsequent successful development of intravenous ligand-mimetic inhibitors occurred during a time of limited understanding of integrin physiology. Although efficient inhibitors of ligand...

Bringing It All Together: Bedside to Bench and Back Again.

From Bench to Business and Back Again

The current emphasis on translational research is starting to blur differences between research environments in academia and industry. This has opened up a two-way street for academic researchers to go to work in industry and, in some cases, to then return to academia.

Coronary microembolization: from bedside to bench and back to bedside.

Coronary microembolization from the erosion or rupture of a vulnerable atherosclerotic plaque occurs spontaneously in acute coronary syndromes and iatrogenically during percutaneous coronary interventions. Typical consequences of coronary microembolization are microinfarcts with an inflammatory response, contractile dysfunction, and reduced coronary reserve. Apart from transient elevations of c...